MiMedx Group Inc. is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its mission is to give physicians products and tissues to help the body heal itself. The company's biomaterial platform technologies include AmnioFix and EpiFix, tissue technologies processed from human amniotic membrane that is derived from donated placentas. MiMedx processes the human amniotic membrane with its proprietary Purion process to produce a safe and effective implant. MiMedx is the leading supplier of amniotic tissue, having supplied over 250,000 allografts to date for application in the wound care, surgical, sports medicine, ophthalmic and dental sectors of healthcare.
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Due to permission requirements, not all quotes are shown.
MiMedx Group Inc. Content
Back to Top